WITH the exit of Britain from the European Union, the European Medicines Agency (EMA) is set to move its headquarters to the Netherlands (PD 21 Nov 2017) but in the process, looks to lose more staff than anticipated.
The move is planned for Mar 2019 but an expected loss of around 30% of staff is reducing the capacity of the agency to the point where it has had to announce "temporary cuts in activities".
Not only did more staff than anticipated choose not to relocate, but employment rules in Amsterdam complicate the issue by disallowing 135 short-term contract staff from working for the EMA.
In a statement, the EMA said, "In the short- to mid-term, EMA will have to reprioritise its resources to fully maintain its core activities related to the evaluation and supervision of medicines to the level of quality and within the timelines expected".
Activities that may be affected include some international collaboration efforts, guideline revisions, some non-product working parties and more.
Visit ema.europa.eu for details.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Aug 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Aug 18
